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Fuelling Cytokine Secretion
in iNKT Cells
In this issue of Immunity, Bezbradica et al. (2006) un-
cover an unsuspected role for the cytokine GM-CSF
in the thymic development of invariant NKT cells, a
role that licenses these cells to secrete effector cyto-
kines upon activation in the periphery.
Invariant natural killer T (iNKT) cells, named for their ex-
pression of a Va14Ja18 (or homologous Va24Ja18 in
humans) T cell receptor (TCR) in conjunction with NK-
cell-associated receptors, are curious beasts indeed
(Kronenberg, 2005). iNKT cells are bone-marrow-derived
cells that develop in the thymus when their stochastically
rearranged TCR engages an endogenous glycolipid pre-
sented by CD1d on double-positive thymocytes. Selec-
tion mediates intrathymic expansion and the acquisition
of their primary effector function, which is the capacity to
secrete cytokines rapidly. Thereafter, iNKT cells are ex-
ported to the periphery, where they take up residence
in bone marrow, spleen, and liver, making up, in mice,
about one million cells in each organ, and up to 30% of
total liver lymphocytes. Development of iNKT cells rea-
ches adult numbers at five or six weeks after birth and
is unaffected by germ-free conditions or the absence
of the cells’ selecting ligand, CD1d, in the periphery.
Interest in iNKT cells picked up with the observation
that injection of mice with anti-CD3 or a-galactosylcer-
amide (a glycolipid derived from sea sponges, or per-
haps from the bacteria that colonize them; see below)
that binds to CD1d and mimics the endogenous ligand
resulted in the appearance, entirely dependent on the
presence of iNKT cells, of cytokines in serum between
30 and 90 min. Thus, iNKT cells, in contrast to conven-
tional ab T cells, do not require priming to release cyto-
kines after receptor ligation and, further, do not demon-
strate the cross-silencing of the interferon-g (IFN-g) and
interleukin-4 (IL-4) genes that restrains the coordinate
production of these cytokines by polarized conventional
CD4+ T cell subsets. Indeed, iNKT cells acquire their ca-
pacity for rapid cytokine production in the thymus by
a process that involves chromatin modifications around
the cytokine genes associated with expression compe-
tence (Stetson et al., 2003). These observations have
driven research by a number of groups seeking to use
the capacity of these cells to secrete cytokines rapidly
as a means to alter the outcomes of a variety of infec-
tious, inflammatory, autoimmune, and neoplastic condi-
tions, with varying success. What has actually driven
their evolutionary place in the vertebrate T cell reper-
toire is a matter of opinion, but perhaps the most telling
observation in mice remains the inability of iNKT-defi-
cient animals to control certain infections. These infec-
tions include certain a-Proteobacteria, a large family
of Gram-negative bacteria, including Sphingomonas,
Rickettsia, and Ehrlichia, some of which totally lacklipopolysaccharide (LPS), but express glycosphingoli-
pids in their outer membranes and thus must be sensed
and controlled by methods independent of toll-like re-
ceptor 4 (TLR4). Some of the glycosylceramides from
the cell walls of such organisms can be presented by
CD1d and can activate iNKT cells (Kinjo et al., 2005;
Mattner et al., 2005).
In this issue of Immunity, Bezbradica et al. add another
wrinkle to the perplexing biology surrounding this un-
usual cell lineage. The authors had previously found that
iNKT development was blocked in the absence of signal-
ing through the transcription factor NF-kB, but that these
cells could be rescued by the antiapoptotic transgene
Bcl-xL. Although cells survived, their function was not re-
stored, suggesting additional downstream targets of
NK-kB that are independent of survival pathways. Noting
that the cytokine GM-CSF is an NF-kB target gene and
that mice deficient in the common b-chain (bc) receptor
shared by IL-3, IL-5, and GM-CSF demonstrate poor
iNKT development, the authors examined the role of
GM-CSF in iNKT cells. Despite fairly normal numbers
and phenotypic appearance of iNKT cells in the absence
of GM-CSF, the capacity of these cells to secrete cyto-
kines was compromised. This functional impairment
was not related to differences in TCR expression, proxi-
mal signaling, or transcription of the cytokine loci during
development, none of which were affected. Indeed, in-
tracellular amounts of IFN-g and IL-4 were intact, and,
at least in the case of IFN-g, the cytokine was polarized
to the synapse in activated iNKT cells. Unexpectedly,
however, iNKT cells from GM-CSF-deficient mice failed
to secrete these proteins, as assessed by a striking de-
crease in cytokines as detected by ELISA or ELISPOT as-
says. Indeed, activation led to failure to expose other-
wise sequestered lysosomal markers, such as LAMP-1,
which become transiently expressed at the membrane
after activation and membrane exocytosis in T cells.
The defect, as established by both in vitro and bone-mar-
row chimera experiments, was intrinsic to iNKT cells and
did not reflect dysregulated trafficking of CD1d or en-
dogenous glycolipid molecules, for instance, because
GM-CSF-deficient antigen-presenting cells are capable
of activating wild-type iNKT cells without difficulty. The
defect is acquired during thymic development, because
it cannot be rescued by providing exogenous GM-CSF to
mature GM-CSF-deficient iNKT cells in vitro or in vivo, but
it can be rescued by providing exogenous GM-CSF to thy-
mocytes from 3–21-day-old GM-CSF-deficient mice ex
vivo. In keeping with just how unusual the iNKT lineage
is, cytokine secretion from activated CD8+ T cells, NK
cells, and polarized CD4+ T cells from GM-CSF-deficient
mice is unaffected. The authors suggest that GM-CSF in-
duces something during a window of thymic develop-
ment that licenses mature iNKT cells to secrete cyto-
kines after activation in the periphery, seemingly in a
lineage-specific manner.
It may be worth stepping back to review the most
striking phenotype in GM-CSF- and bc-deficient mice
and humans. Whether established by gene targeting
(mice), mutations (congenital human in the bc receptor
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394Figure 1. Defects in Vesicular Fusion Events
in GM-CSF-Deficient Immune Cells
Alveolar macrophages (top panels) ingest
aggregates of surfactant proteins and phos-
pholipids for catabolism by lysosomal fusion
through a developmental maturation process
mediated by GM-CSF induction of the tran-
scription factor PU.1. In the absence of GM-
CSF, ingested aggregates fail to be degraded
in lysosomes, resulting in the appearance of
‘‘foamy’’ macrophages and the accumulation
of nondegraded lipid aggregates in the alveo-
li, a disease known as alveolar proteinosis. In
NKT cells (bottom panels), activation through
the invariant TCR results in rapid secretion of
IL-4 and IFN-g. In the absence of GM-CSF
stimulation during thymic development, NKT
cells in the periphery generate IL-4 and IFN-
g in response to TCR stimulation, but are un-
able to secrete cytokines into the extracellu-
lar space. It is not known whether induction
of PU.1 during thymic maturation is responsi-
ble for the later block in cytokine secretion in
peripheral NKT cells.used by GM-CSF), or the presence of autoantibodies to
the cytokine (acquired human autoimmune disease), the
major consequence of GM-CSF deficiency in mice and
humans relates to failure of terminal differentiation of al-
veolar macrophages, resulting in the disease alveolar
proteinosis (Trapnell et al., 2003) (Figure 1). Alveolar
proteinosis is characterized by the accumulation in the
alveoli of large amounts of lipoproteinaceous material,
which seriously compromises air exchange. The alveo-
lar macrophages are foamy and filled with bits of lipid
debris, including large amounts of surfactant proteins.
Patients are susceptible to a variety of airborne infec-
tious diseases, particularly organisms with lipid-rich
outer membranes, such as mycobacteria and nocardia
species. As worked out in mice, the disease does not
reflect excessive production of surfactants, which are
a group of phospholipoproteins secreted by alveolar
type II epithelial cells and not only are microbial opso-
nins, but also work primarily to decrease surface ten-
sion, allowing the smooth expansion of alveoli at the
air-liquid interface where gas exchange occurs. Rather,
terminal differentiation of alveolar macrophages re-
quires the expression of PU.1, a transcription factor that
drives a number of genes involved in processes that fa-
cilitate the catabolism of the surfactant-lipid complexes
to mediate homeostasis, turnover, and re-use of the
building blocks. In turn, PU.1 expression in these cells
is highly dependent on GM-CSF. Thus, the defect can
be rescued by using GM-CSF (less efficiently in people,
where adequate delivery can be a problem) or bypassed
by expression of PU.1 in alveolar macrophages. Intrigu-
ingly, Ets proteins, including PU.1, have been implicated
in transcriptional regulation of CD1d (Geng et al., 2005)
and in IL-4 expression in Th2 cells (Chang et al., 2005),
suggesting a possible link to the NKT pathway. Al-
though examination of the role of PU.1 in NKT cells is
difficult because of the global effects on hematopoiesis
in the absence of this transcription factor, a more cir-
cumspect consideration of its role may be warranted.
iNKT cells can be activated by glycolipids derived frommycobacteria, and a careful look at iNKT activity in hu-
mans with GM-CSF deficiency may point to an underly-
ing reason why these patients have such a propensity to
suffer infections by these organisms and nocardia,
which share a lipid-rich membrane.
One might speculate whether proteins involved in the
terminal secretion of cytokines from iNKT cells might
also function during the uptake and recycling of phos-
pholipid complexes in alveolar macrophages, and per-
haps a closer look is warranted here as well. Rather sur-
prisingly, not much is known regarding the secretory
pathway for effector cytokines. Studies in polarized
CD4+ T cell subsets suggest that these two cytokines
are secreted by different pathways, with IFN-g directed
to the synapse and IL-4 secreted less directionally, al-
though this has not been evaluated in iNKT cells (Huse
et al., 2006). Greater than 60 Rab proteins serve to escort
vesicular cargo for fusion between membrane compart-
ments throughout the cell, and defects in some have
been associated with profound disruption of secretory
granule exocytosis by surprisingly restricted types of
cells, such as cytotoxic T lymphocytes and melanocytes
or melanocytes and platelets (Stinchcombe et al., 2004).
Wherever the defect lies, the discovery by Bezbradica
et al. offers a promising lead into discerning the mecha-
nisms surrounding the last checkpoint before cytokines,
perhaps the most potent effector molecules of the im-
mune system, are launched into (extracellular) space.
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Unraveling the Warp and Weft
of B Cell Fate
Two recent Immunity articles (Enzler et al., 2006; Sasa-
ki et al., 2006) probe the roles of Nuclear Factor k-B
(NF-kB) pathways in survival and differentiation medi-
ated by B cell activation factor of the TNF family
(BAFF).
The characterization of B cell activation factor of the
TNF family (BAFF, also termed BLyS) and its principal
receptor, BAFF-R, has provoked reassessment of the
notion that B cell receptor (BCR) signaling alone gov-
erns B cell survival and selection. Indeed, BAFF-R mu-
tations yield inordinate death among primary B cells de-
spite functional BCRs (Harless et al., 2001); and excess
BAFF fosters humoral autoimmunity in spite of normal
BCR diversity (Mackay et al., 1999). Nonetheless, the
BCR is equally critical to B cell survival (Lam et al.,
1997), and the outcome of BAFF signaling varies in the
context of both BAFF availability and BCR specificity
(Lesley et al., 2004; Thien et al., 2004). Thus, probing
BAFF signal transduction is a key first step towards re-
vealing why these two systems, while both necessary,
operate properly only in concert.
The nuclear factor-kB (NF-kB) family is an attractive
starting point for interrogation because its members
act downstream of several B cell surface molecules, in-
cluding CD40, Toll-like receptors (TLRs), and the BCR
(Figure 1). At least two pathways can initiate formation
of active NF-kB transcriptional regulators. The classical
(NF-kB1) pathway involves kinase cascades that de-
grade inhibitory complexes, affording nuclear localiza-
tion of active dimers; whereas the nonclassical (NF-
kB2) pathway regulates the formation of p52 via p100
degradation. Prior studies suggest that both pathways
are activated by BAFF (Hatada et al., 2003), and knock-
outs for either NF-kB essential modulator (NEMO) or for
NF-kB-inducing kinase (NIK)—upstream components
of NF-kB1 and NF-kB2 pathways, respectively—show
reduced B cell numbers reminiscent of BAFF-R defects.
Accordingly, two recent Immunity articles (Enzler et al.,
2006; Sasaki et al., 2006) have employed powerful gene-Mattner, J., Debord, K.L., Ismail, N., Goff, R.D., Cantu, C., Zhou, D.,
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knockout and transgenic strategies to probe the role of
each NF-kB pathway in BAFF-mediated survival and
selection.
Citing the similarities between NEMO- and BAFF-R-
deficient phenotypes, Sasaki et al. reason that enforced
NF-kB1 activity should circumvent BAFF-R defects and
restore B cell survival. They test this idea by character-
izing mice in which a constitutively active IkB Kinase 2
(IKK2ca) is expressed in mice lacking BAFF-R. These
mice exhibit B cell subset distributions similar to those
of BAFF-R-sufficient controls, and their B cells display
characteristics associated with BAFF-R function, such
as nuclear exclusion of protein kinase-Cd (PKC-d) and
upregulation of Bcl-2 family members including Bcl-xl
and A1. Nonetheless, several observations hint at addi-
tional requirements for optimal BAFF signaling. First, as
the authors note, NEMO deficiency yields a milder B cell
phenotype than does BAFF-R deficiency. Second,
IKK2ca expression in BAFF-R-sufficient mice yields
about twice as many B cells as it does in the BAFF-R
knockouts, suggesting BAFF-R per se provides addi-
tional, non-redundant signals. Finally, BCR signaling re-
mains necessary for fully appropriate responses to this
arm of the BAFF-R cascade; IKK2ca fails to rescue mar-
ginal-zone development in mice lacking the BCR core-
ceptor component CD19.
Enzler et al. not only examine survival but also exploit
the emergence of autoreactivity as a measure of
BAFF-R activity in vivo. Consistent with Sasaki et al.,
they find that BAFF-R activates the NF-kB1 pathway
and influences BAFF-mediated survival in vitro. How-
ever, they find that NF-kB2 is necessary for optimal sur-
vival, as well as for maximal upregulation of Bcl-2 gene
family members. Moreover, they observe a strict NF-
kB2 requirement for induction of the pro-survival kinase
Pim-2 and resultant Bad phosphorylation. Thus, al-
though NF-kB1 is clearly important for BAFF-R signal-
ing, NF-kB2 seems necessary for full function. Extend-
ing the suggestion of such complementary roles to an
in vivo system, they assess how blocking each pathway
impacts marginal-zone differentiation and autoantibody
formation in BAFF transgenics. They find that BAFF sig-
naling through NF-kB2 upregulates integrins and leads
to marginal-zone retention and survival of autoreactive
B cells; their findings extend earlier reports that showed
